Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study

• Published in: Supportive care in cancer Vol. 24; no. 2; pp. 933 - 941
• Main Authors: Tanaka, Yoshihiro, Takahashi, Takao, Yamaguchi, Kazuya, Osada, Shinji, Shimokawa, Toshio, Yoshida, Kazuhiro
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2016; Springer; Springer Nature B.V
• Subjects: Administration, Oral; Aged; Aged, 80 and over; Amine Oxidase (Copper-Containing) - metabolism; Body Weight; Cancer patients; Cancer research; Care and treatment; Chemotherapy; Diet; Esophageal cancer; Esophageal Neoplasms - drug therapy; Feasibility Studies; Female; Food, Formulated; Glutamine; Glutamine - administration & dosage; Humans; Induction Chemotherapy - adverse effects; Male; Medicine; Medicine & Public Health; Middle Aged; Mucositis - chemically induced; Mucositis - diet therapy; Mucositis - prevention & control; Nursing; Nursing Research; Oncology; Original; Original Article; Oxidases; Pain Medicine; Prevention; Rehabilitation Medicine; Stomatitis - chemically induced; Stomatitis - diet therapy; Stomatitis - prevention & control; Studies; Chemotherapy; Elemental diet; Mucositis; Esophageal cancer; Glutamine
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-015-2864-9

Purpose We investigated the effect of glutamine (Gln) and an elemental diet (ED) on chemotherapy-induced oral mucositis in esophageal cancer patients. Methods Thirty patients were randomized to the control group (no treatment: n  = 10), Gln group (oral intake of 8910 mg Gln/day: n  = 10), or Gln plus ED group (total oral intake of 8862 mg Gln/day, including the Gln in ED: n  = 10). Oral administration of Gln and ED began 1 week before chemotherapy and continued during treatment. Oral mucositis was evaluated during 2 cycles of chemotherapy using Common Terminology Criteria for Adverse Events v3.0. Results The incidence of grade ≥2 oral mucositis was 60 % in the control group, 70 % in the Gln group, and 10 % in the Gln plus ED group. Gln plus ED showed a significant preventive effect on the development and severity of oral mucositis. By multivariate analysis, Gln plus ED and cancer stage were independent factors affecting chemotherapy-induced oral mucositis. The percentage of change in body weight and diamine oxidase activity from before chemotherapy was higher in the Gln plus ED group than in the control group. Conclusions Oral administration of Gln plus ED may prevent chemotherapy-induced oral mucositis in esophageal cancer patients.